AIEQ0.050%
as of Jul 20
COR
GrowthCENCORA, INC.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S.
Close · 3M
-15.98%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals4
Win rate75% (3/4)
Avg buy return+4.46%
AIEQ · Weight decrease · 2d
The Amplify ETFs AIEQ fund executed a gradual then rapid reduction in its COR weighting, decreasing from 0.4000% to 0.3900% before a significant cut to 0.0500% within two days. This cadence is characteristic of AIEQ's strategy, which relies on IBM Watson's NLP analysis for daily rankings and EquBot's risk overlay for swift, high-turnover rebalancing. Operating at $288.42, 77% of its 52-week high, and having experienced a -21.2% 90-day return, CENCORA likely presented signals that Watson's broad data ingestion identified as a deteriorating outlook. The fund's hybrid style suggests that any positive financial metrics, such as COR's 115.93% ROE, were likely overshadowed by negative sentiment or adverse fundamental shifts detected by the NLP engine from news, filings, or social posts. Such a decisive, quick divestment highlights AIEQ's reactive investment process, where adverse information concerning COR at its current valuation leads to immediate portfolio adjustments.
weight 0.400% → 0.050% (-0.350 pp)·stock up 9.0% in the 30 days before
Jul 1·entry $288.42·now $303.99
+5.40%
since Jul 1
AIEQ · Weight increase · 2d
AIEQ’s recent adjustment in Cencora shows a granular, step-wise weight increase, moving from 0.39% to 0.40% on the latest recorded days, following prior fluctuations and a rebound from 0.37%. This daily rebalancing, characteristic of Amplify’s high-turnover strategy, aligns with Cencora's current price position: trading at 77% of its 52-week high after a significant 90-day decline, but having posted a 12.2% gain over the last 30 days. IBM Watson’s NLP engine likely identified positive shifts in sentiment or news flow around the Health Care company, coinciding with its recovering price action and strong underlying fundamentals like a 115.93% Return on Equity. The fund's broad market, fundamentals + sentiment hybrid style would interpret this combination of a recent price rebound from a low point and sustained core financial strength as a compelling input for a renewed allocation.
weight 0.370% → 0.400% (+0.030 pp)·stock up 6.0% in the 30 days before
Jun 25·entry $286.95·now $303.99Drifting
+5.94%
since Jun 25
AIEQ · Weight increase · 2d
COR’s 115.93% ROE, paired with 5.95% revenue growth, likely drew AIEQ's attention as its IBM Watson NLP-driven method prioritizes fundamental strength within a broad market approach. Despite a PER of 21.49 and PBR of 40.18, these valuation metrics appear to be considered alongside a potentially shifting sentiment signal, given the stock's 30-day return of -8.6% and trading at $281.48, approximately 75% of its 52-week high. The fund initiated a series of daily weight adjustments for COR, moving from 0.3600% on June 3rd to 0.4000% by June 11th, consistent with EquBot's high-turnover strategy of responding to evolving sentiment and fundamental scores as the stock traded significantly below its recent highs. This consistent increase in allocation suggests IBM Watson's analysis of news, filings, and social posts registered a positive inflection point for COR during a period when its price had seen a 90-day decline of 22.2%, indicating the AI detected value or an improving outlook amidst a downturn.
weight 0.380% → 0.400% (+0.020 pp)·stock up 7.9% in the 30 days before
Jun 11·entry $281.48·now $303.99Drifting
+8.00%
since Jun 11
AIEQ · Weight increase · 2d
weight 0.360% → 0.380% (+0.020 pp)·stock up 8.8% in the 30 days before
Jun 7·entry $274.08·now $303.99Chased
+10.91%
since Jun 7
AIEQ · Sudden change · 1d
The AI ETF likely increased its weight in COR due to the company's exceptional 101.43% ROE, signaling strong underlying profitability, before significantly reducing exposure, possibly due to profit-taking or concerns over the very high PER and PBR valuations becoming unsustainable. For retail investors, this illustrates how AI funds react swiftly to changes in perceived value, emphasizing the risk of holding highly valued stocks when sentiment shifts, even if fundamentals appear strong.
weight 0.610% → 0.270% (-0.340 pp)·stock down 4.3% in the 30 days before
May 3·entry $303.66·now $303.99
+0.11%
since May 3
AMOM · Exit · 1d
The AI ETF likely divested from COR due to its extremely high PER and PBR ratios, suggesting the stock was significantly overvalued despite strong ROE and decent revenue growth. For a retail investor, this highlights the importance of scrutinizing valuation multiples to avoid overpaying for an asset, even for profitable companies, as AI models prioritize risk mitigation from overextended stocks.
weight 1.150% → 0 (exited)·stock down 6.5% in the 30 days before
May 4·entry $303.66·now $303.99
+0.11%
since May 4
AMOM · Weight decrease · 2d
The AI likely initiated the weight decrease due to COR's extremely high PER and PBR ratios, suggesting the stock may be significantly overvalued despite its impressive ROE and revenue growth. This action could signify the system is taking profits or rebalancing to mitigate risk from premium valuations. For retail investors, this highlights that even fundamentally strong companies can prompt AI funds to reduce exposure if valuation becomes stretched, underscoring the importance of considering PER and PBR alongside profitability and growth.
weight 1.210% → 1.150% (-0.060 pp)·stock down 4.3% in the 30 days before
May 1·entry $304.00·now $303.99
0.00%
since May 1
AMOM · Weight decrease · 7d
weight 1.320% → 1.200% (-0.120 pp)·stock down 3.8% in the 30 days before
Apr 22·entry $308.30·now $303.99
-1.40%
since Apr 22
AMOM · Weight decrease · 7d
weight 1.350% → 1.230% (-0.120 pp)·stock down 4.4% in the 30 days before
Apr 21·entry $312.39·now $303.99
-2.69%
since Apr 21
AMOM · Weight decrease · 7d
weight 1.390% → 1.260% (-0.130 pp)·stock down 2.6% in the 30 days before
Apr 20·entry $323.01·now $303.99
-5.89%
since Apr 20
AMOM · Weight decrease · 7d
weight 1.400% → 1.270% (-0.130 pp)·stock up 0.7% in the 30 days before
Apr 17·entry $327.56·now $303.99
-7.20%
since Apr 17
AMOM · Weight decrease · 7d
weight 1.420% → 1.270% (-0.150 pp)·stock down 3.7% in the 30 days before
Apr 16·entry $322.37·now $303.99
-5.70%
since Apr 16
AMOM · Weight decrease · 6d
weight 1.420% → 1.290% (-0.130 pp)·stock down 8.2% in the 30 days before
Apr 15·entry $317.58·now $303.99
-4.28%
since Apr 15
AMOM · Weight decrease · 5d
weight 1.420% → 1.310% (-0.110 pp)·stock down 8.4% in the 30 days before
Apr 10·entry $320.82·now $303.99
-5.25%
since Apr 10
AMOM · Weight decrease · 4d
weight 1.420% → 1.320% (-0.100 pp)·stock down 8.4% in the 30 days before
Apr 9·entry $322.46·now $303.99
-5.73%
since Apr 9
AMOM · Weight decrease · 3d
weight 1.420% → 1.350% (-0.070 pp)·stock down 10.2% in the 30 days before
Apr 8·entry $324.93·now $303.99
-6.44%
since Apr 8
AMOM · Weight decrease · 2d
weight 1.420% → 1.390% (-0.030 pp)·stock down 10.5% in the 30 days before
Apr 7·entry $320.89·now $303.99
-5.27%
since Apr 7
AMOM · Weight decrease · 2d
weight 1.230% → 1.180% (-0.050 pp)·stock down 14.5% in the 30 days before
Apr 1·entry $317.66·now $303.99
-4.30%
since Apr 1
-8.36%
since Mar 19
QRFT · Exit · 1d
The AI likely removed COR due to its extremely high valuation metrics (PER of 36.35, PBR of 40.18), indicating it became significantly overvalued, despite strong ROE and decent revenue growth. This action highlights that even profitable companies can be deemed too expensive, urging retail investors to always consider a stock's valuation alongside its financial performance before investing.
weight 0.140% → 0 (exited)·stock down 6.5% in the 30 days before
May 4·entry $303.66·now $303.99
+0.11%
since May 4
-7.01%
since Mar 20
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of May 2
The AI ETFs, particularly AMOM, are showing a recent trend of decreasing their weight in Cencora. This activity aligns with the framework's 'Fail' verdict, suggesting smart money might also be detecting concerns about the company's valuation or financial sustainability at current prices.
- Circle of CompetenceThe pharmaceutical distribution industry, while complex, has stable unit economics and a predictable role in the healthcare supply chain, allowing for reasonable projection of future cash flows.
- Economic MoatCencora benefits from a strong scale-driven cost advantage in pharmaceutical distribution, high switching costs for customers, and established logistical networks that create a durable economic moat.
- ManagementManagement's candor, capital allocation discipline, and skin in the game cannot be assessed with the provided financial snippets.
- Financial HealthThe exceptionally high single-year ROE of 101.43% suggests a highly leveraged capital structure or a very small equity base, raising concerns about 'undue leverage' and preventing a confident assessment of long-term financial health without more detailed balance sheet and historical performance data.
- Margin of SafetyThe current valuation multiples, including a PER of 37.12 and PBR of 40.18, indicate a high market valuation relative to earnings and book value, suggesting no discernible margin of safety at the current price.
Cencora operates within a stable industry and possesses a strong economic moat due to its scale and entrenched position. However, the available financial data, particularly the exceptionally high single-year ROE without context on leverage, prevents a confident assessment of its financial health. Furthermore, the current valuation multiples suggest the stock is trading at a significant premium, leaving no margin of safety for investors.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.